BostonGene’s mission is to power healthcare’s transition to personalized medicine using AI-based molecular and immune profiling to improve the standard of care, accelerate research, and improve economics. BostonGene Tumor PortraitTM Tests reveal key drivers of each tumor, including immune microenvironment properties, actionable mutations, biomarkers of response to diverse therapies, and recommended therapies. Through these comprehensive analyses, BostonGene Tumor PortraitTM Tests generate a personalized roadmap for therapeutic decision-making for each cancer patient. For more information, visit BostonGene at www.BostonGene.com

CanWell is a venture backed, clinical stage biotech company committed to developing FIC IO medicines. Our pipeline includes multiple modalities: small molecule, SMDC and ADC. To learn more, please visit www.canwellbiotech.com

Catalyst Oncology is a full-service, specialty contract research organization (CRO) built to serve the global biotech industry. Backed by leading retention rates and a culture rooted in its core values, Catalyst Oncology provides customers with teams experienced across all functions, knowledgeable in complex drug classes and study designs, and with data-centric methodologies that help bring next-generation therapies to cancer patients. Connect with Catalyst Oncology on LinkedIn. For more information, visit https://catalystcr.com/catalyst-oncology/oncology-cro/

The Center for Breakthrough Medicines (CBM) is an advanced therapy contract development and manufacturing organization (CDMO) uniquely positioned to enable pharma and biotech companies to develop, test and manufacture life-saving therapies on a global scale. CBM offers scalable, best-in-class capabilities for every stage of development – from IND through commercialization. To learn more, please visit www.breakthroughmedicines.com

Defence Therapeutics is a publicly-traded Canadian biotechnology company working on developing the next generation of vaccines and antibody-drug conjugate (“ADC”) products using its versatile proprietary platform ACCUMTM. The core of Defence Therapeutics platform is the ACCUMTM, a technology specially engineered to enable the design of novel cellular vaccines for the precision delivery of vaccine antigens and any ADCs in their intact form to target cells. As a result, significant increased efficacy and potency can be reached against catastrophic illness such as any type of cancers and infectious diseases. ACCUMTM DRUG THE UNDRUGGABLETM. To learn more, please visit www.defencetherapeutics.com

Elpiscience is a clinical-stage biopharmaceutical company focused on developing next-generation immunotherapies to benefit cancer patients worldwide. Elpiscience has a robust pipeline of globally innovative cancer immunotherapies covering a wide range of oncology targets. Through internal R&D expertise and partnerships with global biopharmaceutical companies, Elpiscience endeavors to advance at least one innovative program into clinic each year.  To learn more please visit www.elpiscience.com

Emergence Therapeutics develops novel ADCs. Our lead program is a next-generation Nectin-4 ADC with superiority over enfortumab vedotin, a high-profile ADC for urothelial cancer. To learn more, please visit www.emergencetx.com

ENB Therapeutics is a clinical stage privately held company developing therapies to treat drug resistant cancers by reprogramming the tumor microenvironment. Our lead product, ENB-003, is a First-in-Class, small molecule, selective endothelin B receptor inhibitor that overcomes immunotherapy resistance across multiple cancer indications in preclinical studies. ENB-003 dramatically enhances anti-PD1 efficacy and when combined with CAR-T, eradicates most tumors within 3 weeks. In our ongoing international Phase 1 trial in collaboration with Merck, ENB-003, in combination with pembrolizumab, is well tolerated and demonstrates encouraging efficacy signals in drug refractory, heavily pre-treated pancreatic cancer, ovarian cancer and melanoma. ENB-003 is the key to unlocking new therapeutic markets in indications that do not respond to immunotherapies such as anti-PD1/PDL1, CTLA-4, CAR-T and cancer vaccines. To learn more, please visit www.enbpharma.com

We deliver powerful, reliable tools that fuel scientific discoveries and drive exponential progress to master biology to advance human health. Cited in more than 4,100 research papers, our innovative single cell, spatial, and in situ technologies enable discoveries across oncology, immunology, neuroscience, and more. Our talented, dedicated science professionals have a distinguished record of creating innovative instruments, reagents, and software that analyze biological systems at a resolution that matches the complexity of biology. To learn more, visit https://www.10xgenomics.com/

Halloran is a life science consulting firm that provides strategic regulatory, quality, clinical, and organizational support to industry leaders and startup visionaries in the pharmaceutical, biotechnology, and med-device sectors. Our consultants are subject matter experts who deliver a tailored approach to each engagement, successfully propelling our clients to their next inflection point.To learn more, visit https://www.hallorancg.com/

A market leader in immuno-oncology imaging, we are focused on non-invasive, whole body, in vivo Immuno-PET imaging of CD8 T cells, using proprietary Minibody technology. By visualize the immune system’s response to therapy and tailoring immuno-oncology treatments our aim is to create a better way to prove cancer treatments work. 

Imaging Endpoints (IE) is the largest oncology-focused imaging CRO globally and is widely recognized for conducting the industry’s largest, most complex, and most successful imaging trials for both solid and liquid tumor indications. Additionally, IE is the global expert in CD8 PET imaging. IE is based in Scottsdale, AZ with offices around the world including Cambridge, MA; London, United Kingdom; Basel, Switzerland; Leiden, Netherlands; Hyderabad, India; and Shanghai, China. Learn more at www.imagingendpoints.com.